Ardelyx Inc 's Cash & cash equivalent grew by 1.24 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Ardelyx Inc 's Quick Ratio to 2.23, Quick Ratio remained below Ardelyx inc average.

Within Major Pharmaceutical Preparations industry 284 other companies have achieved higher Quick Ratio than Ardelyx Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1116 to 1357.

Explain Quick Ratio?
How much Cash & cash equivalents ARDX�s has?
What are ARDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ARDX/financial-strength

https://api.csimarket.com/api/v1/companies/ARDX/fundamentals

https://api.csimarket.com/api/v1/companies/ARDX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ARDX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	53.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	17.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.23	Subscribe	Subscribe	Subscribe	Subscribe
ARDX's Total Ranking	# 1357	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-3.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	1.24 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 285
Healthcare Sector	# 489
Overall Market	# 1357

Quick Ratio Statistics
High	Average	Low
25.52	6.2	1.66
(Jun 30 2015)		(Jun 30 2022)

Financial Statements
Ardelyx Inc 's Current Liabilities	$ 128 Millions	Visit ARDX's Balance sheet
Ardelyx Inc 's Cash & cash equivalent	$ 285 Millions	Visit ARDX's Balance sheet
Source of ARDX's Sales		Visit ARDX's Sales by Geography

Cumulative Ardelyx Inc 's Quick Ratio

ARDX's Quick Ratio for the trailling 12 Months

ARDX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	43.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	13.2 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	2.34	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4027	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	10.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	4.15 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ARDX Financial Strength Comparisons >> Go to Compare ARDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $127.80 millions, cumulative Quick Ratio decreased to 2.34 below the Ardelyx Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Ardelyx Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3706 to 4027.

Explain Quick Ratio?
How much Cash & cash equivalents ARDX�s has?
What are ARDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 438
Healthcare Sector	# 901
Within the Market	# 4027

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.34	3.89	0.57
(Mar 31 2016)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Olema Pharmaceuticals Inc	5.98	$ 413.771 Millions	$ 69.233 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions
United Therapeutics Corporation	5.51	$ 3,439.800 Millions	$ 624.300 Millions
Immuneering Corporation	5.45	$ 58.776 Millions	$ 10.791 Millions
Talphera Inc	5.29	$ 24.508 Millions	$ 4.630 Millions
Rocket Pharmaceuticals Inc	5.22	$ 279.470 Millions	$ 53.508 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Diamedica Therapeutics Inc	4.68	$ 34.905 Millions	$ 7.454 Millions
Eledon Pharmaceuticals Inc	4.61	$ 69.672 Millions	$ 15.099 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Adial Pharmaceuticals Inc	4.35	$ 22.000 Millions	$ 5.056 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Serina Therapeutics Inc	4.28	$ 19.403 Millions	$ 4.529 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Bio Green Med Solution Inc	4.24	$ 3.454 Millions	$ 0.815 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions

Date modified: 2026-11-06T12:58:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.